Avior Wealth Management’s Nuvectis Pharma NVCT Stock Holding History

Avior Wealth Management’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1	Closed	-$8	–	3216
2024 Q1	$8	Buy	+1	New	+$9	﹤0.01%	3788

Other funds holding NVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Avior Wealth Management's NVCT Position: Q2 2024 in Review

Avior Wealth Management sold out of Nuvectis Pharma (NVCT) in Q2 2024, closing a stake of 1 share — an estimated $8 sold.

Avior Wealth Management first reported a position in NVCT in Q1 2024 and held it in 1 quarter. The position peaked at $8 in Q1 2024. 41 funds tracked by Wall St. Rank hold NVCT as of Q2 2024.

Avior Wealth Management reported no remaining Nuvectis Pharma position as of Q2 2024 after selling out during the quarter.
Avior Wealth Management sold 1 Nuvectis Pharma share in Q2 2024, an estimated $8.
Avior Wealth Management first reported a position in Nuvectis Pharma in Q1 2024 and held it in 1 quarter.
Avior Wealth Management's Nuvectis Pharma position peaked at $8 in Q1 2024.
41 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.